21
12

RESULTS Act

10/7/2025, 8:05 AM

Summary of Bill HR 5269

This bill, titled "To amend title XVIII of the Social Security Act to provide long-term stability for Medicare beneficiary access to clinical diagnostic laboratory tests," was introduced in the 119th Congress as H.R. 5269 on September 10, 2025. The bill aims to improve the accuracy of and feasibility of data collection for the private payor-based fee schedule payment rates applied under the Medicare program for such tests, in order to ensure long-term stability for Medicare beneficiaries' access to these tests.

Current Status of Bill HR 5269

Bill HR 5269 is currently in the status of Bill Introduced since September 10, 2025. Bill HR 5269 was introduced during Congress 119 and was introduced to the House on September 10, 2025.  Bill HR 5269's most recent activity was Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. as of September 10, 2025

Bipartisan Support of Bill HR 5269

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
74
Democrat Cosponsors
39
Republican Cosponsors
35
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 5269

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 5269

To amend title XVIII of the Social Security Act to provide long-term stability for Medicare beneficiary access to clinical diagnostic laboratory tests by improving the accuracy of, and feasibility of data collection for, the private payor-based fee schedule payment rates applied under the Medicare program for such tests, and for other purposes.
To amend title XVIII of the Social Security Act to provide long-term stability for Medicare beneficiary access to clinical diagnostic laboratory tests by improving the accuracy of, and feasibility of data collection for, the private payor-based fee schedule payment rates applied under the Medicare program for such tests, and for other purposes.

Comments